Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D

StatusActive, Not Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Apr 2027 → Oct 2027
See other at-risk trials from Alveus Therapeutics, Inc.

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing
    • Primary completion pushed from Apr 2027 to Oct 2027
    • Study completion date: Sep 2027 to Oct 2027
    • Site details revised at 3 of 3 sites
  2. Study sites: 2 to 3
    • Eligibility criteria expanded, about 12 words
  3. Eligibility criteria shortened, about 1 wordv4
  4. Secondary endpoints: details revised at 1 of 10 entriesv3
  5. Study sites: 1 to 2v2
  6. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Alveus Therapeutics, Inc.
2 trials monitored
See 1 trial at risk
Diabetes
5,101 trials monitored
See 233 trials at risk
Obesity
3,888 trials monitored
See 157 trials at risk
Type 2 Diabetes
2,236 trials monitored
See 113 trials at risk
A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes
Trial Details
NCT Number NCT07399678
Lead Sponsor Alveus Therapeutics, Inc.
Conditions
(from sponsor)		 Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes
Related terms Diabetes Mellitus, Type 2, Obesity, Overweight, Weight Loss
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov